PTEN inhibitors Myriad Details Companion Dx Strategy for PARP, PTEN Inhibitors at Goldman Sachs Conference Premium "Myriad is very much a player in the field of companion diagnostics," Myriad Genetics CEO Peter Meldrum told investors at the Goldman Sachs annual global healthcare conference earlier this month. Breaking News 10x Genomics Q4 Revenues Fall 10 Percent, In Line With Preliminary Estimates Grail Stock Surges on Quest Diagnostics Integration of Galleri MCED Test Cell-Free DNA Analysis Predicts Preeclampsia Risk Waters Q4 Revenues Rise 6 Percent Craig-Hallum Initiates Coverage of Myriad Genetics With a Buy Rating